Jasper Therapeutics Inc (JSPR) - Net Assets
Based on the latest financial reports, Jasper Therapeutics Inc (JSPR) has net assets worth $3.40 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.18 Million) and total liabilities ($17.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check JSPR intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.40 Million |
| % of Total Assets | 16.05% |
| Annual Growth Rate | -23.73% |
| 5-Year Change | -94.03% |
| 10-Year Change | N/A |
| Growth Volatility | 124.11 |
Jasper Therapeutics Inc - Net Assets Trend (2019–2025)
This chart illustrates how Jasper Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See JSPR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Jasper Therapeutics Inc (2019–2025)
The table below shows the annual net assets of Jasper Therapeutics Inc from 2019 to 2025. For live valuation and market cap data, see JSPR company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $4.15 Million | -93.27% |
| 2024-12-31 | $61.67 Million | -21.37% |
| 2023-12-31 | $78.44 Million | +117.96% |
| 2022-12-31 | $35.99 Million | -48.23% |
| 2021-12-31 | $69.52 Million | +297.89% |
| 2020-12-31 | $-35.13 Million | -266.48% |
| 2019-12-31 | $21.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jasper Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 31152600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.07% |
| Other Components | $320.82 Million | 7728.69% |
| Total Equity | $4.15 Million | 100.00% |
Jasper Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Jasper Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Intrasense
PA:ALINS
|
$13.06 Million |
|
Copaur Minerals Inc
V:CPAU
|
$13.08 Million |
|
RENEWABLE VENTURES NORDIC
F:X72
|
$13.08 Million |
|
Barunson Co. Ltd
KQ:018700
|
$13.09 Million |
|
Park Ha Biological Technology Co., Ltd.
NASDAQ:PHH
|
$13.04 Million |
|
Guardforce AI Co Ltd
NASDAQ:GFAI
|
$13.04 Million |
|
Skin Elements Ltd
AU:SKN
|
$13.04 Million |
|
Trust Finance Indonesia Tbk
JK:TRUS
|
$13.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jasper Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 61,674,000 to 4,151,000, a change of -57,523,000 (-93.3%).
- Net loss of 75,801,000 reduced equity.
- Share repurchases of 243,000 reduced equity.
- New share issuances of 33,968,000 increased equity.
- Other factors decreased equity by 15,447,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-75.80 Million | -1826.09% |
| Share Repurchases | $243.00K | -5.85% |
| Share Issuances | $33.97 Million | +818.31% |
| Other Changes | $-15.45 Million | -372.13% |
| Total Change | $- | -93.27% |
Book Value vs Market Value Analysis
This analysis compares Jasper Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.74x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.00x to 1.74x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $119.90 | $0.47 | x |
| 2020-12-31 | $-203.08 | $0.47 | x |
| 2021-12-31 | $61.01 | $0.47 | x |
| 2022-12-31 | $9.87 | $0.47 | x |
| 2023-12-31 | $7.51 | $0.47 | x |
| 2024-12-31 | $4.23 | $0.47 | x |
| 2025-12-31 | $0.27 | $0.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jasper Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1826.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 8.62x
- Recent ROE (-1826.09%) is below the historical average (-313.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -23.63% | 0.00% | 0.00x | 1.29x | $-7.10 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.16 Million |
| 2021 | -44.07% | -494.46% | 0.07x | 1.35x | $-37.59 Million |
| 2022 | -104.71% | -278.92% | 0.28x | 1.34x | $-41.28 Million |
| 2023 | -82.18% | 0.00% | 0.00x | 1.21x | $-72.31 Million |
| 2024 | -115.56% | 0.00% | 0.00x | 1.30x | $-77.44 Million |
| 2025 | -1826.09% | 0.00% | 0.00x | 8.62x | $-76.22 Million |
Industry Comparison
This section compares Jasper Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jasper Therapeutics Inc (JSPR) | $3.40 Million | -23.63% | 5.23x | $13.05 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Jasper Therapeutics Inc
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commerci… Read more